Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thromboxane

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Thromboxane. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-002980-24 Sponsor Protocol Number: ASA-001 Start Date*: 2014-07-01
    Sponsor Name:IRCCS San Raffaele di Roma
    Full Title: Comparative study to evaluate the effect on platelet aggregation of two different doses (20 and 40 mg) of acetylsalicylic acid administered sublingually compared to the dose of 100 mg of acetylsali...
    Medical condition: Patients with moderate/high cardiovascular risk
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000920-25 Sponsor Protocol Number: STH19177 Start Date*: 2016-04-15
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A study of very low dose twice-daily compared to standard low dose once-daily aspirin following acute coronary syndromes - WILL lOWer dose aspirin be more effective following ACS?
    Medical condition: Acute coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000017-20 Sponsor Protocol Number: ASS-Metamizol-DDI Start Date*: 2018-07-17
    Sponsor Name:Universitäts-Herzzentrum Freiburg • Bad Krozingen
    Full Title: Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole)
    Medical condition: Antithrombotic therapy after surgical replacement of stenotic heart valve by a bioprosthesis or mitral valve repair
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005163-94 Sponsor Protocol Number: BAY81-8781/12946 Start Date*: 2010-10-08
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment v...
    Medical condition: Acute coronary syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002143-29 Sponsor Protocol Number: 10378/13 Start Date*: 2013-08-03
    Sponsor Name:POLICLINICO GEMELLI
    Full Title: Pharmacological modulation of inflammation and platelet activation in inflammatory bowel diseases
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001971-61 Sponsor Protocol Number: SALYCENDO Start Date*: 2016-08-29
    Sponsor Name:Radboudumc
    Full Title: The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia.
    Medical condition: We will investigate the effects of acetylsalicylic acid on immunoparalysis following human endotoxemia in healthy male volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002209-20 Sponsor Protocol Number: 2015/222/HP Start Date*: 2017-10-05
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: PRODIGE 50 - ASPIK : French prospective randomised double blind study on aspirin versus placebo in resected colon cancer with PI3K mutation stage III or II high risk
    Medical condition: Mutated PI3K colonic adenocarcinoma patients with surgical resection R0
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007647-14 Sponsor Protocol Number: Nabu1A2 Start Date*: 2009-01-07
    Sponsor Name:Turku University Hospital
    Full Title: The effect of fluvoxamine and ciprofloxacin on the pharmacokinetics and pharmacodynamics of nabumetone: A three-phase double-blind placebo-controlled cross-over study.
    Medical condition: Pharmacokinetics and pharmacodynamics, healthy volunteer trial
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003611-21 Sponsor Protocol Number: 2013-003611-21 Start Date*: 2013-12-20
    Sponsor Name:Karolinska Institutet
    Full Title: Safety of fluconazol treatment of premature and full-term newborns - a study on interactions by NSAIDs with fluconazole in respect of pharmacodynamic endpoints with urinary excretion of vas...
    Medical condition: Fungal infection prophylaxis Patent ductus arteriosus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10034130 Patent ductus arteriosus PT
    16.1 10021881 - Infections and infestations 10028924 Neonatal candida infection PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002799-42 Sponsor Protocol Number: CAPstatin2013 Start Date*: 2014-03-27
    Sponsor Name:Dipartimento di Medicina Interna e Specialità Mediche - Policlinico Umberto I - Sapienza Università di Roma
    Full Title: Statins in the prevention of myocardial damage in pneumonia
    Medical condition: Patients hospitalized with community-acquired pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001368-22 Sponsor Protocol Number: DG-041-CV-008 Start Date*: 2006-06-01
    Sponsor Name:deCODE genetics ehf.
    Full Title: A randomized, double blind, placebo controlled phase II evaluation of the pharmacokinetics, pharmacodynamics and safety of DG-041 in PAD patients
    Medical condition: Peripheral arterial disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001232-42 Sponsor Protocol Number: RGHT000270 Start Date*: 2006-06-14
    Sponsor Name:Royal Group of Hospitals Trust
    Full Title: The Pharmacogenetics of Aspirin Resistance
    Medical condition: Aspirin resistance: Vascular diseases are common problems and aspirin is used as an anti-platelet drug to prevent thrombosis. However, aspirin's anti-platelet effect may not be uniform in all patie...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001653-28 Sponsor Protocol Number: 03/314 Start Date*: Information not available in EudraCT
    Sponsor Name:The Leeds teaching Hospitals NHS trust
    Full Title: A comparison of the effects on prostaglandin synthesis and cytokine production of an olive-oil based lipid emulsion (Clinoloeic) with a soya based emulsion (Intralipid) in newborn infnats receiving...
    Medical condition: Prematurity Parenteral nutrition
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-005262-31 Sponsor Protocol Number: CL2-18886-031 Start Date*: 2008-12-02
    Sponsor Name:INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
    Full Title: Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study...
    Medical condition: Ischaemic stroke
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043647 Thrombotic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000942-11 Sponsor Protocol Number: 140207 Start Date*: 2008-04-30
    Sponsor Name:Medizinische Universität Wien/ Universitätsklinik für Innere Medizin II/ Angiologie und Kardiologie
    Full Title: Vienna-Resistance to Antithrombotic Therapy (REACT)
    Medical condition: Resistance to Aspirin and Clopidogrel
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003072-31 Sponsor Protocol Number: 2378 Start Date*: 2018-05-15
    Sponsor Name:VU University Medical Center
    Full Title: The effects of sex hormone administration on marrow and visceral adiposity
    Medical condition: Healthy transgender persons (the effect of differences in sex hormones on the amount of bone marrow fat)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003985-25 Sponsor Protocol Number: SER150-P-C-001 Start Date*: 2015-06-12
    Sponsor Name:Serodus ASA
    Full Title: Multi-centre, randomized, double-blind, placebo-controlled, phase II study assessing in two sequential cohorts the safety, efficacy and tolerability of a 15 mg BID and a 30 mg BID doses of SER150TB...
    Medical condition: type II diabetic patients with diabetic nephropathy and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10012658 Diabetic complications renal HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004632-69 Sponsor Protocol Number: P060309 Start Date*: 2006-12-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Polymorphismes du gène codant pour le cytochrome 2C19 et réponse au clopidogrel chez le sujet sain
    Medical condition: volontaire sain
    Disease: Version SOC Term Classification Code Term Level
    8.1 10043414 Therapeutic response decreased PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-006130-12 Sponsor Protocol Number: Asperum Start Date*: 2021-03-25
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Multicenter randomized, double-blind, placebo-controlled, clinical trial of Acetylsalicylic acid in the prevention of severe COVID-19 pneumonia in hospitalised patients (Asperum)
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10076502 Viral pneumonitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002734-20 Sponsor Protocol Number: CS/2014/4525 Start Date*: 2014-10-23
    Sponsor Name:Research and Innovation Department
    Full Title: A Randomised Controlled Trial Investigating the Pharmacodynamic Effect of Ticagrelor Monotherapy on Platelet Reactivity in Patients with Coronary Artery Disease: The TEMPLATE Study
    Medical condition: Coronary artery disease previously treated with coronary stenting
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    19.0 10007541 - Cardiac disorders 10023024 Ischaemic heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Apr 29 06:18:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA